Future of mRNA Vaccines Beyond COVID-19

by

The COVID-19 pandemic brought along many unprecedented developments in vaccine technology, especially through the successful deployment of mRNA vaccines. Apart from their efficacy in containing the COVID-19 pandemic, these vaccines have already offered early proof of mRNA technology’s potential to revolutionize the field of vaccines. What is the future for mRNA vaccines beyond the immediate crisis of pandemic management? This paper underscores how the vaccination technology associated with mRNA could come into play beyond COVID-19, exhibiting versatility, challenges, and promising lines of inquiry into the future.

The Versatility of mRNA Technology

mRNA vaccines represent huge potential in their design and manufacturing because of their rapidity, thus offering a singular platform for the development of vaccines against many diseases. High mRNA vaccines differ from the traditional vaccine in that, unlike the latter, using live attenuated or inactivated viruses to confer immunity, the former does not require but a minute fraction of the pathogen genetic material. Via such instruction, cells of the body produce a protein to which it later responds to the immune system. The technology is faster to develop and more flexible for researchers to react in time against any emerging infectious diseases.

One of the most auspicious applications of mRNA vaccines in the near future is in fighting influenza. Seasonal influenza remains one of the most significant public health threats, with the virus constantly mutating, at times rendering traditional vaccines less effective. The potential of mRNA vaccines to better target specific strains of the influenza virus makes it suitable for potentially offering broader and more durable protection. Moreover, mRNA technology is flexible enough to be rapidly updated in order to address new strains once they appear. The updating would occur similar to the way that COVID-19 mRNA vaccines were updated for the point of attack against different variants of the SARS-CoV-2 virus.

mRNA Vaccines in Oncology

In addition to infectious diseases, the technology of the mRNA vaccine makes a lot of sense in oncology. The development of cancer vaccines, as research, may be rather ancient, but maybe the processes of cancer as an illness were too difficult for effective vaccines to be developed. mRNA vaccines represent a new generation of development that allows for truly personalized cancer vaccine designs based on the specific profile of the patient’s tumor. Such vaccines encode tumor-specific mutated antigens and, after administration, elicit an immune response against cancer cells but not healthy tissues.

Preliminary clinical trials have already given encouraging results, especially in patients suffering from melanoma. In the case of such clinical trials, mRNA vaccines have been used to induce an immune response against cancer cells and are reportedly resulting in significant tumor regression in some cases. mRNA vaccines could be combined with other forms of immunotherapy, such as checkpoint inhibitors, which would raise their therapeutic promise. This increases the likelihood of effective and long-lasting antitumor responses.

Another area that work is going on is the development of mRNA vaccines against chronic diseases such as cardiovascular disease, diabetes, and neurodegenerative disorders. Each has a huge burden of health worldwide. Conventional approaches to vaccination have been limited in combating these conditions, but mRNA technology opens a range of new opportunities against such diseases. For instance, the mRNA can be generated to express therapeutic proteins or enzymes that are lacking in various chronic diseases. This offers potential as a new means of managing such diseases that avoids continuous medication and potentially even offers longer-lasting effects.

An interesting application of mRNA vaccines is in neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Studies on the use of mRNA vaccines for the expression of proteins that counteract the pathologies underlying these diseases are underway. This work is at an early stage but could eventually bring out some really improved treatments that delay or prevent debilitating neurodegenerative conditions.

Yearwise Publication Trend on “mrna vaccines”

Find publication trends on relevant topics

Addressing Challenges

While mRNA vaccines are hugely promising, there are still several challenges to be overcome if the full potential of this technology is to be realized. Of these, the first concerns the stability of the mRNA molecules themselves. mRNA is an intrinsically rather fragile and readily degraded molecule. One reason the mRNA vaccines against COVID-19 were so remarkably successful was the development of lipid nanoparticles that encapsulate the mRNA, protecting it and rendering it easier to enter cells. The currently used mRNA delivery systems need further improvements to achieve increased stability and efficacy for a more extended period of applications.

One major concern is that of possible adverse immune reactions. While mRNA vaccines have generally been well-tolerated, some rare but serious side effects have been noted, particularly myocarditis, especially in the young. Such side effects must be understood in their occurrence, with parallel development of preventing measures taken alongside the broadened use of mRNA vaccines.

Furthermore, the high cost of mRNA vaccine production itself acts as a barrier to its wide application, mainly in low- and middle-income countries. Improvement in manufacturing processes will be needed, and more cost-effective methods for production will have to be developed in order to guarantee that the benefit of mRNA vaccines reaches all populations.

Future Outlook

If looked at from the future perspective, mRNA vaccines have a very bright future in front of them. The speed at which COVID-19 mRNA vaccines were developed and rolled out has exposed a new approach to vaccine innovation, that of feasibility and proof of principle for mRNA technology. This means that, moving forward, mRNA vaccines will be sitting right at the very heart of fighting a huge array of diseases, ranging from infectious pathogens to chronic and complex conditions.

While mRNA vaccines have huge potential to be tailored against any given disease, parallel ongoing improvements in the delivery systems and manufacturing processes are only the tip of the iceberg of what this technology is capable of. Further research into mRNA vaccine technology can potentially lead to even higher applicability and impacts on global health.

Recent Publications on “mrna vaccines”

Find publications on relevant topics

Conclusion

Though the potential uses for mRNA vaccines certainly extend beyond COVID-19. This flexibility, coupled with the potential to be developed within an extremely short period on the brink of global outbreaks or an epidemic, places mRNA vaccines among one of the most revolutionary developments in medicine. There are many challenges for which solutions are to be addressed, but current research and innovation look set to pave the way for mRNA vaccines to really change the way diseases are prevented and treated for years to come. The possibilities for mRNA technology in developing medicines for improved health outcomes globally are immense and truly exciting.

References

  1. Pardi, N., Hogan, M.J., Porter, F.W. and Weissman, D., 2018. mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 17(4), pp.261-279.
  2. Jackson, N.A., Kester, K.E., Casimiro, D., Gurunathan, S. and DeRosa, F., 2020. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines, 5(1), p.11.
  3. Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D. and Brachtendorf, S., 2020. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), pp.594-599.
  4. Haque, A. and Pant, A.B., 2020. Efforts at COVID-19 vaccine development: challenges and successes. Vaccines, 8(4), p.739.
  5. Hogan, M.J. and Pardi, N., 2022. mRNA vaccines in the COVID-19 pandemic and beyond. Annual review of medicine, 73(1), pp.17-39.
  6. van Riel, D. and de Wit, E., 2020. Next-generation vaccine platforms for COVID-19. Nature materials, 19(8), pp.810-812.
  7. Pardi, N., Hogan, M.J., Porter, F.W. and Weissman, D., 2018. mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 17(4), pp.261-279.
  8. Anderson, E.J., Rouphael, N.G., Widge, A.T., Jackson, L.A., Roberts, P.C., Makhene, M., Chappell, J.D., Denison, M.R., Stevens, L.J., Pruijssers, A.J. and McDermott, A.B., 2020. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine, 383(25), pp.2427-2438.

Top Experts on “mrna vaccines“